Company Updates - On December 29, 2025, the company announced a long-term strategic partnership with Lanacheng to advance the development of Radionuclide drug conjugates (RDCs) [1] - The collaboration aims to leverage the proprietary Harbour Mice platform to produce fully human monoclonal antibodies in H2L2 and HCAb formats, which are expected to enhance the efficacy of RDCs while reducing side effects [1] Collaborations and Agreements - The company has established multiple overseas licensing agreements, including a long-term global strategic cooperation with BMS on December 17, 2025, which includes an upfront payment of $90 million and potential milestone payments up to $1.035 billion [1] - On November 19, 2025, the company's subsidiary, Nona Bio, signed a non-exclusive licensing agreement with Pfizer for preclinical antibody discovery, granting Pfizer global rights to the HCAb platform, with upfront and milestone payments based on regulatory and clinical achievements [1] - On November 24, 2025, the company announced an expanded collaboration with AstraZeneca, extending the partnership to include ADC and TCE drugs [2] Financial Forecast and Valuation - Due to increased revenue from business development upfront payments, the company raised its 2026 profit forecast by 228% to $6.2 million and introduced a new profit forecast of $6.0 million for 2027 [2] - The target price has been adjusted upward by 34.3% to HKD 18.00, indicating a potential upside of 44.5% from the current stock price [2]

Group 1 - The core viewpoint of the report is that due to the upfront payment from the collaboration with BMS, the company has raised its 2026 profit forecast by 228% to USD 0.62 billion and introduced a new profit forecast for 2027 at USD 0.60 billion [1] - The target price has been increased by 34.3% to HKD 18.00, indicating a potential upside of 44.5% from the current stock price [1] Group 2 - The company announced a long-term strategic partnership with Blue Nanotech on December 29, 2025, to advance the development of next-generation radionuclide drug conjugates (RDCs) [2] - The proprietary Harbour Mice platform allows the company to produce fully human monoclonal antibodies in H2L2 and HCAb formats, which have lower immunogenicity, superior tissue penetration, and high specificity and stability, enhancing the efficacy of RDC drugs while reducing side effects [3] - The company has established multiple overseas licensing collaborations, including a long-term global strategic cooperation agreement with BMS on December 17, 2025, which includes an upfront payment of USD 90 million and potential milestone payments of up to USD 1.035 billion [3] - A non-exclusive licensing agreement was signed with Pfizer on November 19, 2025, for advancing preclinical antibody discovery for various potential diseases, with upfront payments and milestone payments based on regulatory, clinical, and commercialization achievements [3] - The collaboration with AstraZeneca was further deepened on November 24, 2025, expanding the scope to include ADC and TCE drugs [3]